Abstract
INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel. ARIES (Avastin Regimens: Investigation of Effectiveness and Safety), a prospective observational cohort study, evaluated outcomes in a large, community-based population of patients with first-line NSCLC. METHODS: From 2006 to 2009, ARIES enrolled patients with locally advanced or metastatic NSCLC who were eligible for bevacizumab, excluding those with predominantly squamous histology. Patients were required to provide informed consent and to have initiated bevacizumab with chemotherapy within 4 months before enrollment. There were no protocol-defined treatments or assessments. The dosing of bevacizumab and chemotherapy, and the choice of chemotherapy regimen, was at the discretion of the treating physician. RESULTS: ARIES enrolled 1967 patients with first-line NSCLC. At study closure, median follow-up was 12.5 months (range, 0.2-65.5). Median age was 65 years (range, 31-93), and 252 patients (12.8%) identified as never smokers. Median progression-free survival was 6.6 months (95% confidence interval, 6.3-6.9), and median overall survival was 13.0 months (95% confidence interval, 12.2-13.8) with first-line bevacizumab plus chemotherapy. Incidences of bevacizumab-associated adverse events (19.7% overall) were consistent with those in randomized controlled trials of bevacizumab in NSCLC. CONCLUSION: Results from ARIES demonstrate similar outcomes to randomized controlled trials of bevacizumab when added to standard chemotherapy in a real-world patient population with advanced NSCLC.
| Original language | English |
|---|---|
| Pages (from-to) | 1332-1339 |
| Number of pages | 8 |
| Journal | Journal of Thoracic Oncology |
| Volume | 9 |
| Issue number | 9 |
| DOIs | |
| State | Published - Jan 1 2014 |
Fingerprint
Keywords
- Bevacizumab
- Chemotherapy
- Non-small-cell lung cancer
ASJC Scopus subject areas
- Oncology
- Pulmonary and Respiratory Medicine
Cite this
Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer : Final results of the ARIES observational cohort study. / Lynch, Thomas J.; Spigel, David R.; Brahmer, Julie; Fischbach, Neal; Garst, Jennifer; Jahanzeb, Mohammad; Kumar, Priya; Vidaver, Regina M.; Wozniak, Antoinette J.; Fish, Susan; Flick, E. Dawn; Leon, Larry; Hazard, Sebastien J.; Kosty, Michael P.
In: Journal of Thoracic Oncology, Vol. 9, No. 9, 01.01.2014, p. 1332-1339.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer
T2 - Final results of the ARIES observational cohort study
AU - Lynch, Thomas J.
AU - Spigel, David R.
AU - Brahmer, Julie
AU - Fischbach, Neal
AU - Garst, Jennifer
AU - Jahanzeb, Mohammad
AU - Kumar, Priya
AU - Vidaver, Regina M.
AU - Wozniak, Antoinette J.
AU - Fish, Susan
AU - Flick, E. Dawn
AU - Leon, Larry
AU - Hazard, Sebastien J.
AU - Kosty, Michael P.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel. ARIES (Avastin Regimens: Investigation of Effectiveness and Safety), a prospective observational cohort study, evaluated outcomes in a large, community-based population of patients with first-line NSCLC. METHODS: From 2006 to 2009, ARIES enrolled patients with locally advanced or metastatic NSCLC who were eligible for bevacizumab, excluding those with predominantly squamous histology. Patients were required to provide informed consent and to have initiated bevacizumab with chemotherapy within 4 months before enrollment. There were no protocol-defined treatments or assessments. The dosing of bevacizumab and chemotherapy, and the choice of chemotherapy regimen, was at the discretion of the treating physician. RESULTS: ARIES enrolled 1967 patients with first-line NSCLC. At study closure, median follow-up was 12.5 months (range, 0.2-65.5). Median age was 65 years (range, 31-93), and 252 patients (12.8%) identified as never smokers. Median progression-free survival was 6.6 months (95% confidence interval, 6.3-6.9), and median overall survival was 13.0 months (95% confidence interval, 12.2-13.8) with first-line bevacizumab plus chemotherapy. Incidences of bevacizumab-associated adverse events (19.7% overall) were consistent with those in randomized controlled trials of bevacizumab in NSCLC. CONCLUSION: Results from ARIES demonstrate similar outcomes to randomized controlled trials of bevacizumab when added to standard chemotherapy in a real-world patient population with advanced NSCLC.
AB - INTRODUCTION: Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor, was approved by the US Food and Drug Administration for the treatment of advanced non-small-cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel. ARIES (Avastin Regimens: Investigation of Effectiveness and Safety), a prospective observational cohort study, evaluated outcomes in a large, community-based population of patients with first-line NSCLC. METHODS: From 2006 to 2009, ARIES enrolled patients with locally advanced or metastatic NSCLC who were eligible for bevacizumab, excluding those with predominantly squamous histology. Patients were required to provide informed consent and to have initiated bevacizumab with chemotherapy within 4 months before enrollment. There were no protocol-defined treatments or assessments. The dosing of bevacizumab and chemotherapy, and the choice of chemotherapy regimen, was at the discretion of the treating physician. RESULTS: ARIES enrolled 1967 patients with first-line NSCLC. At study closure, median follow-up was 12.5 months (range, 0.2-65.5). Median age was 65 years (range, 31-93), and 252 patients (12.8%) identified as never smokers. Median progression-free survival was 6.6 months (95% confidence interval, 6.3-6.9), and median overall survival was 13.0 months (95% confidence interval, 12.2-13.8) with first-line bevacizumab plus chemotherapy. Incidences of bevacizumab-associated adverse events (19.7% overall) were consistent with those in randomized controlled trials of bevacizumab in NSCLC. CONCLUSION: Results from ARIES demonstrate similar outcomes to randomized controlled trials of bevacizumab when added to standard chemotherapy in a real-world patient population with advanced NSCLC.
KW - Bevacizumab
KW - Chemotherapy
KW - Non-small-cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=84906242661&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906242661&partnerID=8YFLogxK
U2 - 10.1097/JTO.0000000000000257
DO - 10.1097/JTO.0000000000000257
M3 - Article
C2 - 25122429
AN - SCOPUS:84906242661
VL - 9
SP - 1332
EP - 1339
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
SN - 1556-0864
IS - 9
ER -